NYSE: AZTR · Life Sciences · 8 alerts · CIK 1701478
Share price
$0.6270Close, Nov 16
Market cap
$3.8M
Shares outstanding
6.06MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Azitra, Inc. filings on SEC EDGAR ↗
Azitra, Inc. reported Q3 2026 financial results and provided updates on its dermatology pipeline, including positive ex vivo results for its ATR-COSF cosmetic program and the advancement of ATR-04 into Cohort 2 of its Phase 1/2 trial. The company highlighted that upcoming clinical data readouts could trigger an additional $5.25 million to $10.5 million in investment from existing institutional investors.
Term
Q3 2026
“During the third quarter and recent weeks, we made substantial progress with our two priority programs, generating encouraging results for ATR-COSF and advancing ATR-04 forward in the clinic while broadening its potential to benefit more patients.”
Francisco Salva, Chief Executive Officer
“The remainder of 2026 has the potential to be a defining period for Azitra as we expect to report initial results from our first in-human cosmetic study of ATR-COSF and topline data from Cohort 1 of our ATR-04 Phase 1/2 trial.”
Azitra, Inc. reported a net loss of $10.2 million for the nine months ended September 30, 2026, compared to $8.7 million in the prior year period. The company significantly strengthened its cash position to $3.8 million through a $10.4 million private placement and warrant exercises, while continuing to invest heavily in research and development for its synthetic biology dermatology platform.
Azitra announced positive ex vivo human skin model data for its ATR-COSF program, showing a 56% reduction in wrinkles and improved skin elasticity. The company plans to initiate a first-in-human study for the filaggrin-based topical cosmetic with initial results expected by year-end 2026. Additionally, the company provided updates on its ATR-04 Phase 1/2 trial, which has been expanded to include patients with rashes from KRAS and MEK inhibitors.
Azitra has amended its Phase 1/2 clinical trial protocol for ATR-04 to expand patient eligibility to include those with rashes caused by KRAS and MEK inhibitors, as well as NF1 patients. The company also shortened required washout periods for antibiotics and steroids to accelerate patient recruitment and enrollment for Cohort 2 of the study.
Azitra Deal Termination with A.G.P./Alliance Global Partners
Azitra, Inc. announced it has decided to suspend and not utilize its at-the-market (ATM) offering program with A.G.P./Alliance Global Partners for the foreseeable future. The company cited its current capital resources, upcoming milestones, and the dilutive effect of equity issuances as reasons for the decision. Separately, the company released positive ex vivo study data for its ATR-COSF cosmetic program showing improvements in skin elasticity and fine lines.
Azitra, Inc. has filed a certificate of amendment to effectuate a 1-for-10 reverse stock split of its common stock, effective October 26, 2026. The split aims to consolidate every 10 shares into one share to adjust the trading price on the NYSE American. No fractional shares will be issued, with stockholders receiving cash payments in lieu of fractional interests.